Lanean...
The dawn of mRNA vaccines: The COVID-19 case
In less than one year since the outbreak of the COVID-19 pandemic, two mRNA-based vaccines, BNT162b2 and mRNA-1273, were granted the first historic authorization for emergency use, while another mRNA vaccine, CVnCoV, progressed to phase 3 clinical testing. The COVID-19 mRNA vaccines represent a new...
Gorde:
| Argitaratua izan da: | J Control Release |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Elsevier B.V.
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8008785/ https://ncbi.nlm.nih.gov/pubmed/33798667 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jconrel.2021.03.043 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|